Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

Abstract

Colorectal cancer (CRC) remains a significant global health challenge, ranking third in incidence and second in mortality among cancers worldwide. This review addresses the complex landscape of CRC, focusing on incidence, mortality trends, preventive strategies, and the evolving therapeutic approaches, particularly highlighting the role of platinum-based drugs like oxaliplatin (OXP). It also underscores the increasing burden of CRC, with factors such as westernized diets, aging populations, and genetic predispositions contributing to its prevalence. Therapeutically, early detection greatly enhances survival rates, emphasizing the importance of regular colonoscopies and stool tests. For advanced CRC, chemotherapy remains pivotal, with OXP as a cornerstone treatment despite its associated chemotherapy-induced peripheral neurotoxicity (CIPN). The review explores innovative strategies to overcome challenges related to chemotherapy, such as drug resistance and side effects, highlighting recent developments in the field, such as Pt(IV) prodrugs and immunotherapeutic approaches to enhance efficacy while minimizing toxicity. Additionally, this manuscript examines experimental models for drug screening, emphasizing the role of murine models and advanced 3D in vitro systems in CRC research. Overall, the review advocates for a comprehensive approach, integrating prevention, early detection, and personalized treatments to alleviate the global burden of CRC.

Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives
Kai H. Lange, Michael P. Dalton, Suraj Kumar Mandal +1
Annual review of pharmacology and toxicology7 Aug 2026Peer-reviewedLicence not statedFull textNeurosciencePMC
Dendritic cell-based vaccines for colorectal cancer: Mechanisms, clinical progress and future directions (Review)
Lian Yih Pong, Siti Ayuni Hassanudin, Seng Kong Tham +4
International Journal of Oncology3 Sep 2026Peer-reviewedCC BY-NC-ND 4.0Full textImmunologyPMC
Emerging drugs in phase 2/3 and selected phase 1/2 cellular-therapy trials: a glimpse into the future of systemic sclerosis treatment
Eisha Naveed, Alain Lescoat, Marco Matucci-Cerinic +16
Annals of the Rheumatic Diseases3 Nov 2026Peer-reviewedCC BY 4.0Full textGeneral biologyHAL
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
Eric Barat, Marianne L.E. Arrii, Annaelle Soubieux-Bourbon +3
The Breast9 Sep 2026Peer-reviewedCC BY-NC-NDFull text3 citedImmunologyHAL
From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells
Esraa A. Salim, Xiaojia Ji, Michael Tarpley +4
PLOS One16 Sep 2026Peer-reviewedCC BY 4.0Full textMolecular biology & gene regulation Cell biologyPLOS

Cite

BibTeX RIS

BibTeX

@article{kee2026colorectal,
  title = {{Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs}},
  author = {Jia Xuan Kee and Jia Ning Nicolette Yau and Ram Pravin Kumar Muthuramalingam and Xinyi Wang and Wei Heng Chng and Alvaro Lopez-Sanchez and Kevin Kuang Wei Tay and Lih-Wen Deng and Dan Gibson and Helene C Bertrand and Giulia Adriani and Wee Han Ang and Giorgia Pastorin},
  journal = {Chemical Reviews},
  year = {2026},
  month = sep,
  doi = {10.1021/acs.chemrev.5c00041},
  url = {https://hal.science/hal-05750549v1},
  note = {CC BY-NC-ND 4.0},
}

RIS

TY  - JOUR
TI  - Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
AU  - Jia Xuan Kee
AU  - Jia Ning Nicolette Yau
AU  - Ram Pravin Kumar Muthuramalingam
AU  - Xinyi Wang
AU  - Wei Heng Chng
AU  - Alvaro Lopez-Sanchez
AU  - Kevin Kuang Wei Tay
AU  - Lih-Wen Deng
AU  - Dan Gibson
AU  - Helene C Bertrand
AU  - Giulia Adriani
AU  - Wee Han Ang
AU  - Giorgia Pastorin
PY  - 2026
DA  - 2026/09/15
JO  - Chemical Reviews
DO  - 10.1021/acs.chemrev.5c00041
UR  - https://hal.science/hal-05750549v1
AB  - Colorectal cancer (CRC) remains a significant global health challenge, ranking third in incidence and second in mortality among cancers worldwide. This review addresses the complex landscape of CRC, focusing on incidence, mortality trends, preventive strategies, and the evolving therapeutic approaches, particularly highlighting the role of platinum-based drugs like oxaliplatin (OXP). It also underscores the increasing burden of CRC, with factors such as westernized diets, aging populations, and genetic predispositions contributing to its prevalence. Therapeutically, early detection greatly enhances survival rates, emphasizing the importance of regular colonoscopies and stool tests. For advanced CRC, chemotherapy remains pivotal, with OXP as a cornerstone treatment despite its associated chemotherapy-induced peripheral neurotoxicity (CIPN). The review explores innovative strategies to overcome challenges related to chemotherapy, such as drug resistance and side effects, highlighting recent developments in the field, such as Pt(IV) prodrugs and immunotherapeutic approaches to enhance efficacy while minimizing toxicity. Additionally, this manuscript examines experimental models for drug screening, emphasizing the role of murine models and advanced 3D in vitro systems in CRC research. Overall, the review advocates for a comprehensive approach, integrating prevention, early detection, and personalized treatments to alleviate the global burden of CRC.
SN  - 0009-2665
SN  - 1520-6890
ER  -

Abstract

Related

Cite